scholarly journals Low morbidity and mortality with COVID‐19 in sickle cell disease: A single center experience

eJHaem ◽  
2020 ◽  
Vol 1 (2) ◽  
pp. 608-614 ◽  
Author(s):  
Preethi Ramachandran ◽  
Abhilash Perisetti ◽  
Balachandar Kathirvelu ◽  
Mahesh Gajendran ◽  
Snigdha Ghanta ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Morbidity And Mortality ◽  
Single Center ◽  
Cell Disease ◽  
Single Center Experience

scholarly journals SICKLE CELL DISEASE MORTALITY IN BRAZIL: A SINGLE-CENTER EXPERIENCE

2021 ◽  
Vol 43 ◽  
pp. S29
Author(s):  
DC Stocco ◽  
FLS Santos ◽  
VEF Costa ◽  
ALL Morais ◽  
GC Santis ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Single Center ◽  
Cell Disease ◽  
Single Center Experience ◽  
Disease Mortality

Veno-Venous Extracorporeal Membrane Oxygenation in Adult Patients with Sickle Cell Disease and Acute Chest Syndrome: a Single-Center Experience

Hemoglobin ◽  
2020 ◽  
Vol 44 (2) ◽  
pp. 71-77
Author(s):  
Ferras Alashkar ◽  
Frank Herbstreit ◽  
Alexander Carpinteiro ◽  
Julia Baum ◽  
Asterios Tzalavras ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Extracorporeal Membrane Oxygenation ◽  
Sickle Cell ◽  
Adult Patients ◽  
Acute Chest Syndrome ◽  
Single Center ◽  
Cell Disease ◽  
Membrane Oxygenation ◽  
Single Center Experience

scholarly journals Sickle Cell Disease and COVID-19 Infection: A Single-Center Experience

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 985-985
Author(s):  
Sindhu Devarashetty ◽  
Kimberly Le Blanc ◽  
Udhayvir Singh Grewal ◽  
Jacqueline Walton ◽  
Tabitha Jones ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Sickle Cell Disease ◽  
Mortality Rate ◽  
Sickle Cell ◽  
Adult Patients ◽  
Living Alone ◽  
Morbidity And Mortality ◽  
Acute Chest Syndrome ◽  
Single Center ◽  
Cell Disease

Abstract Background and Objectives: The COVID-19 (CO19) pandemic caused by SARS-CoV-2 remains a significant issue for global health, economics, and society. Several reports have shown that African Americans (AA) have been disproportionately affected by the CO19 pandemic. Limited data have suggested that sickle cell disease (SCD) could be one of the several reasons for higher morbidity and mortality related to CO19 among AA. Recent reports have suggested higher-than-average morbidity and mortality related to CO19 among patients with SCD. We conducted a retrospective, single-institution study in adult patients with SCD who were diagnosed with CO19 infection and their outcomes. Methods: After IRB approval, we conducted a chart review of adult patients (greater than 18 years) with SCD who were diagnosed with CO19 infection between March 1st, 2020, and March 31st, 2021. We recorded demographic data including age, gender, social factors (the type of insurance, availability of primary care provider (PCP), living alone/not), clinical parameters (type of SCD, co-morbidities), outpatient management of SCD, and how CO19 infection was managed like inpatient admission and complications. In patients who were admitted or seen in the emergency department (ED), we collected additional data including vitals, labs, the severity of illness, complications, length of stay, and outcomes. Computations were performed using statistical software SAS 9.4 for Windows. Results: We found a total of 51 patients with SCD diagnosed with CO19 infection in the above period. The median age of patients was 30 years. 61% were females and 39 % were males. All of them were AA. 11.76% were living alone, 49.02% were living with family, 1.96% (1 patient) was institutionalized, and the living situation was unknown in 37.25%. Most of the patients had Medicaid Insurance (52.94%), Medicare in 33.3%, private insurance in 13.73 % and 2% were uninsured. Only 64.71% of patients had a PCP. 60% had HbSS disease, 32% had HbSC disease, 4% had HbS-beta thalassemia, one patient each had HbSS with hereditary persistence of HbF and HbS/HbD. Comorbidities and previous history included acute chest syndrome in 65.96%, avascular necrosis in 36.96%, leg ulcers in 8.7%, hypertension in 8.7%, sickle cell retinopathy in 14.57%, cerebrovascular disease in 26.19%, chronic kidney disease in 7.69%, venous thromboembolism (VTE) in 20.41%, 10.41% were on anticoagulation, history of HIV and hepatitis C infection in 6.38%. 28.21% of patients were maintained on partial exchange transfusions as an outpatient for various indications. 72.73% were on hydroxyurea, 7.5% were on crizanlizumab, 5.26% were on voxelotor and 26.83% were on iron chelation. Vitals and pertinent lab values on initial assessment were recorded and many patients had missing data. On presentation, 25.53% were febrile, 29.17% of patients were tachycardic, 31.25% were hypoxic (SpO2 < 95%), 38.46% were tachypneic, 59.18% had a body mass index (BMI) of > 24.9. Median hemoglobin and hematocrit were 8.9/27.4 g/dL. The median white blood cell count was 9490/uL and platelets were 315,000/uL. Median ferritin was 1573 ug/L. Median bilirubin and creatinine were 2.05 mg/dL and 0.86 mg/dL. The patients were further stratified based on the clinical location where CO19 infection was managed (Table 1). 39.3% were diagnosed in the outpatient setting/ED and 60.3% in the inpatient setting. Among 51 patients, 5.71% (n=2) required ICU admission and was mechanically ventilated. 17.5% received dexamethasone, 7.69% received remdesivir, 2.76% received convalescent plasma, 17.07% had infections and 47% received antibiotics. Only one patient received an exchange transfusion during admission. One patient developed a new VTE after CO19 infection. On statistical analysis, the only factor which impacted the clinical location of management was tachycardia (P=0.007). Of the 51 patients, only 3.9% (2 patients) died of complications of CO19 infection, one with hypoxic respiratory failure, disseminated intravascular coagulation, shock, and the other one with pulmonary embolism. 13% were readmitted within a month, one of them was admitted with a new pulmonary embolism and the others were admitted for acute painful episodes. Conclusion: We found a mortality rate of 3.9% in our single-center study of patients with SCD and CO19 infection. This mortality rate is lower than other published experiences in patients with SCD and CO19 infection. Figure 1 Figure 1. Disclosures Master: Blue Bird Bio: Current holder of individual stocks in a privately-held company.

scholarly journals Cost Savings with Isovolemic Hemodilution Red Cell Exchange in Sickle Cell Disease Patients: A Single Center Experience

2016 ◽  
Vol 146 (suppl_1) ◽  
Author(s):  
Alexander Feldman ◽  
Rance Siniard ◽  
Elizabeth Staley ◽  
Michael Boshell ◽  
Lance Williams ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Cost Savings ◽  
Red Cell ◽  
Single Center ◽  
Cell Disease ◽  
Isovolemic Hemodilution ◽  
Single Center Experience

Characteristics and outcomes of osteomyelitis in children with sickle cell disease: A 10‐year single‐center experience

2020 ◽  
Vol 67 (5) ◽  
Author(s):  
Julie K. Weisman ◽  
Robert Sheppard Nickel ◽  
Deepika S. Darbari ◽  
Benjamin R. Hanisch ◽  
Yaser A. Diab
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Single Center ◽  
Cell Disease ◽  
Single Center Experience

scholarly journals Integrative Holistic Approaches for Children, Adolescents, and Young Adults with Sickle Cell Disease: A Single Center Experience

2021 ◽  
pp. 102680
Author(s):  
Laila A. Mahmood ◽  
Lisa Thaniel ◽  
Brenda Martin ◽  
Stefanie Marguiles ◽  
Sarah Reece-Stremtan ◽  
...  
Keyword(s):  
Young Adults ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Adolescents And Young Adults ◽  
Single Center ◽  
Cell Disease ◽  
Single Center Experience ◽  
Holistic Approaches
Sign in / Sign up

Export Citation Format

Share Document